Drugs / Esuberaprost
Esuberaprost
also known as
APS 314D · Aps-314d free acid · Beraprost sodium 314d · Beraprost Sodium 314d Modified Release tablets · BPS-314d · ESUBERAPROST POTASSIUM · ESUBERAPROST SODIUM · GP-1681
Small molecule targets PTGIR via activation
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03657095 | Dec 2018 → Jul 2019 | pulmonary arterial hypertension | Lung Biotechnology PBC | Terminated | No outcome recorded |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Esuberaprost | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03657095 ↗ |
| Known as | APS 314D | ChEMBL registry synonym — accepted as the source's own label CHEMBL3137314 ↗ |
| Known as | Aps-314d free acid | ChEMBL registry synonym — accepted as the source's own label CHEMBL3137314 ↗ |
| Known as | Beraprost sodium 314d | ChEMBL registry synonym — accepted as the source's own label CHEMBL3137314 ↗ |
| Known as | Beraprost Sodium 314d Modified Release tablets | “long-term treatment with esuberaprost sodium tablets (Beraprost Sodium 314d Modified Release tablets)” NCT03657095 ↗ |
| Known as | BPS-314d | ChEMBL registry synonym — accepted as the source's own label CHEMBL3137314 ↗ |
| Known as | ESUBERAPROST POTASSIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL3137314 ↗ |
| Known as | ESUBERAPROST SODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL3137314 ↗ |
| Known as | GP-1681 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3137314 ↗ |
| Action | Activate | “Prostanoid IP receptor agonist” CHEMBL3137314 ↗ |
| Modality | Small molecule | — CHEMBL3137314 ↗ |
| Route | Oral | “administered orally QID” NCT03657095 ↗ |
| Target | PTGIR | “Prostanoid IP receptor agonist” CHEMBL3137314 ↗ |